5-132587637-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_005732.4(RAD50):c.832C>T(p.Arg278*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000316 in 1,613,250 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005732.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.832C>T | p.Arg278* | stop_gained | Exon 6 of 25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.535C>T | p.Arg179* | stop_gained | Exon 7 of 26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.0000198 AC: 3AN: 151730Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000439 AC: 11AN: 250612Hom.: 0 AF XY: 0.0000443 AC XY: 6AN XY: 135572
GnomAD4 exome AF: 0.0000328 AC: 48AN: 1461520Hom.: 0 Cov.: 31 AF XY: 0.0000303 AC XY: 22AN XY: 727070
GnomAD4 genome AF: 0.0000198 AC: 3AN: 151730Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74078
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The p.R278* pathogenic mutation (also known as c.832C>T), located in coding exon 6 of the RAD50 gene, results from a C to T substitution at nucleotide position 832. This changes the amino acid from an arginine to a stop codon within coding exon 6. This mutation has been detected in 1/1824 patients with triple negative breast cancer who were unselected for a family history of breast or ovarian cancer (Couch FJ et al. J. Clin. Oncol. 2015 Feb;33:304-11) as well as 1/615 unselected patients with a pancreatic exocrine neoplasm (Lower MA et al. J. Natl. Cancer Inst. 2018 Oct;110(10):1067-1074). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This sequence change creates a premature translational stop signal (p.Arg278*) in the RAD50 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD50 are known to be pathogenic (PMID: 19409520). This variant is present in population databases (rs766315644, gnomAD 0.01%). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 25452441). ClinVar contains an entry for this variant (Variation ID: 408402). For these reasons, this variant has been classified as Pathogenic. -
RAD50-related disorder Pathogenic:1
The RAD50 c.832C>T variant is predicted to result in premature protein termination (p.Arg278*). This variant has been reported in individuals with breast cancer (Table S2, Couch et al. 2015. PubMed ID: 25452441), ovarian cancer (Table S7, Lilyquist et al. 2017. PubMed ID: 28888541), exocrine pancreatic neoplasm (Lowery et al. 2018. PubMed ID: 29506128), and an individual with prostate cancer (Table S1, Nguyen-Dumont et al. 2020. PubMed ID: 32338768). This variant is reported in 0.012% of alleles in individuals of Latino descent in gnomAD and is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/408402/). Nonsense variants in RAD50 are expected to be pathogenic. This variant is interpreted as pathogenic. -
Nijmegen breakage syndrome-like disorder Pathogenic:1
- -
not provided Other:1
Variant interpreted as Uncertain significance and reported on 10-08-2015 by Lab Ambry Genetics. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at